Rhythm Pharmaceuticals, INC Schedule 13G passive stakes

Perceptive Advisors and Joseph Edelman have filed an amendment reporting a 5.1% beneficial ownership stake in Rhythm Pharmaceuticals, Inc.

Vanguard Capital Management has reported beneficial ownership of 5.02% of Rhythm Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Rhythm Pharmaceuticals Inc., reporting a 0% beneficial ownership stake following an internal corporate realignment.

PRIMECAP Management Co. has reported a 5.21% beneficial ownership stake in Rhythm Pharmaceuticals, Inc. as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, revealing a 9.3% beneficial ownership in Rhythm Pharmaceuticals Inc.

PRIMECAP Management Co. reports an updated 6.42% beneficial ownership in Rhythm Pharmaceuticals, Inc. as of September 30, 2025.

The Vanguard Group has increased its beneficial ownership in Rhythm Pharmaceuticals Inc. to 7.52% of common stock.

RA Capital Management and its affiliates reported a continued 8.7% beneficial ownership stake in Rhythm Pharmaceuticals, Inc. as of June 30, 2025.

PRIMECAP Management Co. reports a 7.67% beneficial ownership stake in Rhythm Pharmaceuticals, Inc., holding 4,878,037 common shares as an investment adviser.

Perceptive Advisors LLC and Joseph Edelman, along with affiliated funds, have disclosed a combined beneficial ownership of 6.8% in Rhythm Pharmaceuticals, Inc., totaling 4,423,441 shares.

Baker Bros. Advisors and its affiliates have filed an Amendment No. 7 to Schedule 13G, reporting a continued beneficial ownership of 8.9% of Rhythm Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

PRIMECAP Management Co./CA/ has filed an amended Schedule 13G, reporting a 9.15% beneficial ownership stake in Rhythm Pharmaceuticals, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% passive beneficial ownership stake in Rhythm Pharmaceuticals Inc. as of March 31, 2025.

PRIMECAP Management Co./CA/ has reported a 10.69% beneficial ownership stake in Rhythm Pharmaceuticals, Inc. as of December 31, 2024.

Goldman Sachs Group and its affiliate, Goldman Sachs & Co. LLC, have reported a passive beneficial ownership of 3.0% in Rhythm Pharmaceuticals, Inc. as of December 31, 2024.